Nuvectis Pharma Statistics

Total Valuation

Nuvectis Pharma has a market cap or net worth of $226.43 million. The enterprise value is $214.68 million.

Market Cap	226.43M
Enterprise Value	214.68M

Important Dates

The next estimated earnings date is Tuesday, May 6, 2025, before market open.

Earnings Date	May 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Nuvectis Pharma has 23.39 million shares outstanding. The number of shares has increased by 10.01% in one year.

Current Share Class	23.39M
Shares Outstanding	23.39M
Shares Change (YoY)	+10.01%
Shares Change (QoQ)	+3.06%
Owned by Insiders (%)	45.41%
Owned by Institutions (%)	6.89%
Float	12.77M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	21.00
P/TBV Ratio	24.01
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.09

Current Ratio	2.09
Quick Ratio	2.08
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -173.41% and return on invested capital (ROIC) is -113.21%.

Return on Equity (ROE)	-173.41%
Return on Assets (ROA)	-65.65%
Return on Invested Capital (ROIC)	-113.21%
Return on Capital Employed (ROCE)	-204.33%
Revenue Per Employee	n/a
Profits Per Employee	-$1.46M
Employee Count	13
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.42% in the last 52 weeks. The beta is -0.23, so Nuvectis Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.23
52-Week Price Change	+25.42%
50-Day Moving Average	7.39
200-Day Moving Average	6.66
Relative Strength Index (RSI)	67.09
Average Volume (20 Days)	128,350

Short Selling Information

The latest short interest is 1.49 million, so 6.37% of the outstanding shares have been sold short.

Short Interest	1.49M
Short Previous Month	1.34M
Short % of Shares Out	6.37%
Short % of Float	11.66%
Short Ratio (days to cover)	15.62

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-19.85M
Pretax Income	-21.10M
Net Income	-19.00M
EBITDA	n/a
EBIT	-19.85M
Earnings Per Share (EPS)	-$1.11

Full Income Statement

Balance Sheet

The company has $18.53 million in cash and n/a in debt, giving a net cash position of $18.53 million or $0.79 per share.

Cash & Cash Equivalents	18.53M
Total Debt	n/a
Net Cash	18.53M
Net Cash Per Share	$0.79
Equity (Book Value)	9.71M
Book Value Per Share	0.50
Working Capital	9.71M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-12.25M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nuvectis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.01%
Shareholder Yield	-10.01%
Earnings Yield	-8.15%
FCF Yield	n/a

Analyst Forecast

The average price target for Nuvectis Pharma is $15.00, which is 54.96% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$15.00
Price Target Difference	54.96%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1